Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

Benedict Yan; Ee Xuan Yau; Shoa Nian Choo; Chee Wee Ong; Kol Jia Yong; Brendan Pang; Manuel Salto-Tellez

doi:10.1136/jclinpath-2011-200009

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

Benedict Yan, Ee Xuan Yau, Shoa Nian Choo, Chee Wee Ong, Kol Jia Yong, Brendan Pang, Manuel Salto-Tellez

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.

Original language	English
Pages (from-to)	880-3
Number of pages	4
Journal	Journal of Clinical Pathology
Volume	64
Issue number	10
DOIs	https://doi.org/10.1136/jclinpath-2011-200009
Publication status	Published - Oct 2011

Keywords

Chromosomes, Human, Pair 17
Receptor, erbB-2
Chi-Square Distribution
Humans
In Situ Hybridization, Fluorescence
Biopsy
Predictive Value of Tests
Gene Amplification
False Negative Reactions
In Situ Hybridization
Stomach Neoplasms
Singapore
Tumor Markers, Biological
Immunohistochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jclinpath-2011-200009

Cite this

Yan, B., Yau, E. X., Choo, S. N., Ong, C. W., Yong, K. J., Pang, B., & Salto-Tellez, M. (2011). Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. Journal of Clinical Pathology, 64(10), 880-3. https://doi.org/10.1136/jclinpath-2011-200009

@article{93b279459d634cf3a5b6be33e6b98c1e,

title = "Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples",

abstract = "Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.",

keywords = "Chromosomes, Human, Pair 17, Receptor, erbB-2, Chi-Square Distribution, Humans, In Situ Hybridization, Fluorescence, Biopsy, Predictive Value of Tests, Gene Amplification, False Negative Reactions, In Situ Hybridization, Stomach Neoplasms, Singapore, Tumor Markers, Biological, Immunohistochemistry",

author = "Benedict Yan and Yau, {Ee Xuan} and Choo, {Shoa Nian} and Ong, {Chee Wee} and Yong, {Kol Jia} and Brendan Pang and Manuel Salto-Tellez",

year = "2011",

month = oct,

doi = "10.1136/jclinpath-2011-200009",

language = "English",

volume = "64",

pages = "880--3",

journal = "Journal of Clinical Pathology",

issn = "1472-4146",

publisher = "BMJ Publishing Group",

number = "10",

}

Yan, B, Yau, EX, Choo, SN, Ong, CW, Yong, KJ, Pang, B & Salto-Tellez, M 2011, 'Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples', Journal of Clinical Pathology, vol. 64, no. 10, pp. 880-3. https://doi.org/10.1136/jclinpath-2011-200009

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. / Yan, Benedict; Yau, Ee Xuan; Choo, Shoa Nian et al.
In: Journal of Clinical Pathology, Vol. 64, No. 10, 10.2011, p. 880-3.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

AU - Yan, Benedict

AU - Yau, Ee Xuan

AU - Choo, Shoa Nian

AU - Ong, Chee Wee

AU - Yong, Kol Jia

AU - Pang, Brendan

AU - Salto-Tellez, Manuel

PY - 2011/10

Y1 - 2011/10

N2 - Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.

AB - Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination of HER2 genomic status, brightfield ISH is being increasingly recognised as a viable alternative. Also, the impact of HER2 protein expression/genomic heterogeneity on the accuracy of HER2 testing has not been well studied in the context of gastric biopsy samples.

KW - Chromosomes, Human, Pair 17

KW - Receptor, erbB-2

KW - Chi-Square Distribution

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Biopsy

KW - Predictive Value of Tests

KW - Gene Amplification

KW - False Negative Reactions

KW - In Situ Hybridization

KW - Stomach Neoplasms

KW - Singapore

KW - Tumor Markers, Biological

KW - Immunohistochemistry

U2 - 10.1136/jclinpath-2011-200009

DO - 10.1136/jclinpath-2011-200009

M3 - Article

C2 - 21757431

SN - 1472-4146

VL - 64

SP - 880

EP - 883

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

IS - 10

ER -

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this